期刊
EUROPEAN NEUROPSYCHOPHARMACOLOGY
卷 20, 期 8, 页码 535-544出版社
ELSEVIER SCIENCE BV
DOI: 10.1016/j.euroneuro.2009.12.005
关键词
Major depressive disorder; BDNF; Polymorphism; Treatment response; Meta-analysis
资金
- National Natural Science Foundation of China [30830089]
The aim of our meta-analysis was to assess the association between BDNF Val66Met polymorphism and treatment response in patients with MDD. 8 studies that included data from 1115 subjects were identified. We tested two phenotypes: response rate and remission rate. OR was used as a measure of the effect of the association in a fixed/random effect model. Meta-analysis was performed for genotypes Met/Met versus Val/Val, Val/Met versus Val/Val, Met/Met versus Val/Met, Val/Met+Met/Met versus Val/Val, Met/Met versus Val/Val+Val/Met, and Met allele versus Val allele. When all groups were pooled, a significant association of Val/Met genotype and increased response rate was found in comparison to Val/Val in overall population (OR=1.66, 95%Cl=1.07-2.57, P=0.02). In the subgroup analysis, similar result was shown in Asian population (OR=1.83, 95%Cl=1.03-3.26, P=0.04), but not in Caucasian population. We didn't observe a significant association of BDNF Val66Met polymorphism with remission rate. This meta-analysis demonstrates the association between BDNF Val66Met polymorphism and treatment response in patients with MOD, and Val66Met heterozygous patients have a better response rate in comparison to Val/Val homozygote patients, especially in Asian population. (C) 2010 Elsevier B.V. and ECNP. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据